Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Sacks 128, Delays New Drug Research Center

NEW YORK, Nov. 7-In an effort to trim early-stage research expenses, CuraGen is laying off 128 employees and postponing construction of a new drug research center, the company said today.


The restructuring, which eliminates 25 percent of the company's staff, is intended to save CuraGen money and shift the company's focus toward preclinical and clinical drug development.


It will cost the company roughly $11 million in charges, including $8 million to delay construction of the new facility.


CuraGen had about $431 million in cash and investments as of Sept. 30, 2002, giving the company three to four years worth of funding at an annual burn rate of $80 to $100 million.


GenomeWeb reported earlier this fallthat the company would be taking moves to rein in spending.



The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.